Document Detail


Infarct size as a determinant of acute and long-term prognosis.
MedLine Citation:
PMID:  6400007     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Enzymatic estimates of infarct size based on the analysis of either plasma total or CK-MB activity are substantially larger in patients who succumb to myocardial infarction compared with survivors. Similarly, if patients are stratified according to infarct size calculations, mortality increases as infarct size increases. Enzymatic markers of infarction are closely related to other indicators of prognosis, including infarct type (transmural versus nontransmural), infarct location (anterior versus inferior), the degree of left and right ventricular dysfunction, and the frequency of ventricular dysrhythmia. Hence, at least some of the prognostic impact of these variables may be due to the initial extent of infarction sustained. Multivariate analysis has been employed by several groups to analyze the independent contribution of these clinical descriptors to prognosis after infarction. These analyses have consistently indicated a substantial independent impact of enzymatic estimates of infarct size on prognosis. In studies of patients with initial myocardial infarction, infarct size index calculated from total plasma CK time activity curves had the greatest independent influence on survival. Unfortunately, the utility of enzymatic estimates of infarction as prognostic indicators in individual patients is attenuated by alterations in the strength of the apparent association between CK infarct size and prognosis in specific clinical situations. Thrombolytic therapy is now employed with increasing frequency during acute myocardial infarction. It has become abundantly clear that plasma CK release kinetics are profoundly modified by this procedure. Peak plasma total and CK-MB activity is markedly increased compared with that of patients undergoing routine therapy for infarction, with a profoundly altered CK time activity curve.(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
E M Geltman
Related Documents :
10627877 - Diagnosis and risk stratification of patients with anginal pain and non-diagnostic elec...
9783607 - Evaluation of troponin-i as an indicator of cardiac dysfunction after thermal injury.
15915417 - Evaluation and management of the acutely dyspneic patient: the role of biomarkers.
17213337 - Ischaemia modified albumin in radiofrequency catheter ablation.
10627877 - Diagnosis and risk stratification of patients with anginal pain and non-diagnostic elec...
22196787 - Meta-analysis of ten trials on the effectiveness of the radial versus the femoral appro...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.; Review    
Journal Detail:
Title:  Cardiology clinics     Volume:  2     ISSN:  0733-8651     ISO Abbreviation:  Cardiol Clin     Publication Date:  1984 Feb 
Date Detail:
Created Date:  1986-01-14     Completed Date:  1986-01-14     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  8300331     Medline TA:  Cardiol Clin     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  95-103     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Creatine Kinase / blood
Heart / physiopathology
Humans
Myocardial Infarction / enzymology,  pathology*,  physiopathology
Prognosis
Grant Support
ID/Acronym/Agency:
HL 17646/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
EC 2.7.3.2/Creatine Kinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Exercise testing in the early period after myocardial infarction in the evaluation of prognosis.
Next Document:  Coronary angiographic and morphologic correlation.